PTC Therapeutics, Inc. (PTCT)
63.46
-0.67
(-1.04%)
USD |
NASDAQ |
Oct 02, 16:00
63.49
+0.03
(+0.05%)
After-Hours: 20:00
PTC Therapeutics Research and Development Expense (TTM) : 433.31M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 433.31M |
| March 31, 2026 | 447.15M |
| December 31, 2025 | 455.25M |
| September 30, 2025 | 446.89M |
| June 30, 2025 | 508.14M |
| March 31, 2025 | 527.32M |
| December 31, 2024 | 534.48M |
| September 30, 2024 | 531.06M |
| June 30, 2024 | 533.86M |
| March 31, 2024 | 587.57M |
| December 31, 2023 | 666.56M |
| September 30, 2023 | 733.90M |
| June 30, 2023 | 735.15M |
| March 31, 2023 | 706.54M |
| December 31, 2022 | 651.50M |
| September 30, 2022 | 612.65M |
| June 30, 2022 | 578.03M |
| March 31, 2022 | 546.25M |
| December 31, 2021 | 540.68M |
| September 30, 2021 | 508.85M |
| June 30, 2021 | 471.01M |
| March 31, 2021 | 522.05M |
| December 31, 2020 | 477.64M |
| September 30, 2020 | 441.46M |
| June 30, 2020 | 411.54M |
| Date | Value |
|---|---|
| March 31, 2020 | 294.99M |
| December 31, 2019 | 257.45M |
| September 30, 2019 | 229.27M |
| June 30, 2019 | 220.56M |
| March 31, 2019 | 193.19M |
| December 31, 2018 | 171.98M |
| September 30, 2018 | 147.57M |
| June 30, 2018 | 123.23M |
| March 31, 2018 | 121.46M |
| December 31, 2017 | 117.46M |
| September 30, 2017 | 114.23M |
| June 30, 2017 | 115.60M |
| March 31, 2017 | 113.60M |
| December 31, 2016 | 117.63M |
| September 30, 2016 | 126.67M |
| June 30, 2016 | 125.91M |
| March 31, 2016 | 125.28M |
| December 31, 2015 | 121.82M |
| September 30, 2015 | 113.64M |
| June 30, 2015 | 101.76M |
| March 31, 2015 | 91.89M |
| December 31, 2014 | 79.84M |
| September 30, 2014 | 67.99M |
| June 30, 2014 | 63.11M |
| March 31, 2014 | 59.51M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Biogen, Inc. | 1.736B |
| BioMarin Pharmaceutical, Inc. | 766.68M |
| Arcturus Therapeutics Holdings, Inc. | 79.32M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |